title: The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer.
abstract: The triple therapy of Helicobacter pylori eradication prevents repeated bleeding from stomach ulcer. The aim of this one-way blind prospective study was to evaluate the efficiency of the two-week triple therapy for Helicobacter pylori eradication in preventing renewed bleeding in patients with stomach ulcer within one year. This research included 60 hospitalized patients with bleeding stomach ulcer and positive Helicobacter pylori infection, 34 men and 26 women (average age 59.7 years). The patients were given therapeutic scheme of omeprazol--amoxicilin--metrodinazol (OAM) eradication for 14 days. Eradication of H. pylori infection was defined as lack of proof of the infection one month or several months after therapy suspension. By applying triple OAM therapy within two weeks the eradication was successful in 72%. In the group of 17 H. pylori positive patients there were 8 patients (47.6%) with repeated stomach ulcer and 3 patients (18%) with bleeding. Within the group of 43 H. pylori negative patients there were only 2 patients (4.65%) with repeated stomach ulcer and 1 patient (2%) with bleeding, during the observed period of 12 months. This research confirms the hypothesis about the necessity of eradication of Helicobacter pylori infection in patients with bleeding stomach ulcer as prevention of repeated bleeding.
authors.affiliation: Department of Internal Medicine, University Hospital Osijek, Osijek, Croatia. nhorvat@vip.hr
authors.forename: Darko
authors.initials: D
authors.lastname: Horvat
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Vcev
authors.forename: Ivan
authors.initials: I
authors.lastname: Soldo
authors.forename: Jasna
authors.initials: J
authors.lastname: Timarac
authors.forename: Branko
authors.initials: B
authors.lastname: Dmitrović
authors.forename: Tonci
authors.initials: T
authors.lastname: Misević
authors.forename: Zdravko
authors.initials: Z
authors.lastname: Ivezić
authors.forename: Nikola
authors.initials: N
authors.lastname: Kraljik
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000472:pathogenicity*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D010438:Peptic Ulcer Hemorrhage / Q000209:etiology* / Q000517:prevention & control*; D012008:Recurrence; D013276:Stomach Ulcer / Q000150:complications* / Q000382:microbiology*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D000658:Amoxicillin; D009853:Omeprazole